Shockwave Medical Announces Dan Puckett to Retire as CFO in 2024
11 Septembre 2023 - 10:05PM
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the
development and commercialization of transformational technologies
for the treatment of cardiovascular disease, announced today that
Chief Financial Officer Dan Puckett plans to retire in the first
quarter of 2024. Dan has served as the CFO at Shockwave since he
joined the company in 2016. The Board of Directors has initiated a
process to identify a successor. Mr. Puckett plans to continue as
the Chief Financial Officer until his successor is appointed.
“I want to thank Dan for his years of dedication to Shockwave
and his contributions to our growth and to our success as an
organization,” said Doug Godshall, Chief Executive Officer at
Shockwave. “Under his stewardship, which began before we even sold
our first catheter, we executed multiple rounds of private funding
and ultimately one of the most successful recent IPOs in our
sector. Dan’s hard work helped establish the foundation that
enabled Shockwave to build a unique and differentiated medical
device enterprise in the cardiovascular space. For that, the team
at Shockwave, our customers who use IVL and the many patients who
have benefited from our technologies across the globe are
grateful.”
About Shockwave Medical, Inc. Shockwave
Medical is a leader in the development and commercialization
of novel technologies that transform the care of underserved
patients with cardiovascular disease. Its first-of-its-kind
Intravascular Lithotripsy (IVL) technology has revolutionized the
way calcium is managed during the treatment of atherosclerotic
cardiovascular disease by safely using sonic pressure waves to
disrupt challenging calcified plaque, resulting in significantly
improved patient outcomes. Through the recent acquisition of the
Reducer, which is under clinical investigation in the
U.S. and is CE Marked in the EU and UK, Shockwave
Medical plans to introduce its second transformative technology to
the interventional cardiology community. By redistributing blood
flow within the heart, the Reducer is designed to provide relief to
the millions of patients worldwide suffering from refractory angina
who have no other treatment options. Learn more
at www.shockwavemedical.com and www.neovasc.com.
Forward-Looking StatementsThis press release
contains statements relating to our expectations, activities,
programs, goals, events or developments that we expect, believe or
anticipate will or may occur, which are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements, other than statements of
historical facts, are statements that could be deemed
forward-looking. In some cases, you can identify these statements
by forward-looking words such as “may,” “might,” “will,” “should,”
“expects,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “potential,” or “continue,” and similar expressions,
and the negative of these terms. You are cautioned not to place
undue reliance on these forward-looking statements. Forward-looking
statements are only predictions based on our current plans,
expectations, estimates, and assumptions, valid only as of the date
they are made, and subject to risks and uncertainties, some of
which we are not currently aware.
Important factors that could cause our actual results to differ
materially from those indicated in the forward-looking statements
include, among others: our ability to design, develop, manufacture
and market innovative products to treat patients with challenging
medical conditions, particularly in peripheral artery disease,
coronary artery disease and aortic stenosis; our ability to
successfully execute our commercialization strategy for our
approved or cleared products; and our expected future growth,
including growth in international sales. These factors, as well as
others, are discussed in our filings with the Securities and
Exchange Commission (SEC), including in Part I, Item IA - Risk
Factors in our most recent Annual Report on Form 10-K filed with
the SEC, and in our other periodic and other reports filed with the
SEC. Except to the extent required by law, we do not undertake to
update any of these forward-looking statements after the date
hereof to conform these statements to actual results or revised
expectations.
Media Contact:Scott
Shadiow+1.317.432.9210sshadiow@shockwavemedical.comInvestor
Contact:Debbie Kasterdkaster@shockwavemedical.com
Shockwave Medical (NASDAQ:SWAV)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Shockwave Medical (NASDAQ:SWAV)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024